On-Demand Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Learn how to apply FDA NAM guidance to streamline nonclinical development, support IND decisions, and…

Certara2026 年 5 月 8 日

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026 年 5 月 7 日

Blog

Optimize readiness for MHRA-NICE aligned pathway

Achieve HTA and regulatory success in the MHRA–NICE pathway through early evidence alignment.

Certara2026 年 5 月 1 日

On-Demand Webinar

Compliance? Anywhere, anytime: Automated controlled substance detection and tariff classification at Merck KGaA

Learn how Merck KGaA automates controlled substance detection and HS classification to ensure global compliance…

Certara2026 年 4 月 27 日

Conference

ACS Fall 2026

– – Booth

Certara2026 年 4 月 27 日

Fact Sheet

DIDB® Concomitant Meds Navigator

Explore the Concomitant Meds Navigator withing DIDB - An evidence-based tool within DIDB that helps…

Certara2026 年 4 月 27 日

Blog

ADC dose optimization: Applying model-informed strategies in development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

Certara2026 年 4 月 22 日

药物开发

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Designing Drug Development Programs for Reimbursement Success

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Optimize readiness for MHRA-NICE aligned pathway

Compliance? Anywhere, anytime: Automated controlled substance detection and tariff classification at Merck KGaA

ACS Fall 2026

DIDB® Concomitant Meds Navigator

ADC dose optimization: Applying model-informed strategies in development

订阅时事通讯

快捷链接

解决方案

联系我们